Yonger

Yonger (Suzhou) Biopharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of next-generation small molecule therapeutics for autoimmune and inflammatory diseases. Headquartered in Suzhou, China, the company leverages its expertise in medicinal chemistry to design highly selective kinase inhibitors that aim to improve upon existing treatment standards. Its lead candidate, YG-001, is a potent and selective Tyrosine kinase 2 (TYK2) inhibitor currently undergoing Phase 2 clinical trials for the treatment of plaque psoriasis. The company's pipeline also includes YG-002, a selective Janus kinase 1 (JAK1) inhibitor, and several other programs in early-stage development. Yonger is supported by leading venture capital firms such as GL Ventures and Oriza Holdings, positioning it as a significant player in the Chinese immunology biotech landscape.